MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify SARS-CoV-2 Persistence and Latent Viral Reactivation in Long-COVID
Haddad, N. S.; Morrison-Porter, A.; Quehl, H.; Capric, V.; Lamothe, P. A.; Anam, F.; Runnstrom, M. C.; Truong, A. D.; Dixit, A. N.; Woodruff, M. C.; Chen, A.; Park, J.; Nguyen, D. C.; Hentenaar, I.; Kim, C. Y.; Kyu, S.; Stewart, B.; Wagman, E.; Geoffroy, H.; Sanz, D.; Cashman, K. S.; Ramonell, R. P.; Cabrera-Mora, M.; Alter, D. N.; Roback, J. D.; Horwath, M. C.; O'Keefe, J. B.; Dretler, A. W.; Gripaldo, R.; Yeligar, S. M.; Natoli, T.; Betin, V.; Patel, R.; Vela, K.; Hernandez, M. R.; Usman, S.; Varghese, J.; Jalal, A.; Lee, S.; Le, S. N.; Amoss, R. T.; Daiss, J. L.; Sanz, I.; Lee, F. E.-H.
Show abstract
Post-acute sequelae of SARS-CoV-2 (SARS2) infection (PASC) is a heterogeneous condition, but the main viral drivers are unknown. Here, we use MENSA, Media Enriched with Newly Synthesized Antibodies, secreted exclusively from circulating human plasmablasts, to provide an immune snapshot that defines the underlying viral triggers. We provide proof-of-concept testing that the MENSA technology can capture the new host immune response to accurately diagnose acute primary and breakthrough infections when known SARS2 virus or proteins are present. It is also positive after vaccination when spike proteins elicit an acute immune response. Applying the same principles for long-COVID patients, MENSA is positive for SARS2 in 40% of PASC vs none of the COVID recovered (CR) patients without any sequelae demonstrating ongoing SARS2 viral inflammation only in PASC. Additionally, in PASC patients, MENSAs are also positive for Epstein-Barr Virus (EBV) in 37%, Human Cytomegalovirus (CMV) in 23%, and herpes simplex virus 2 (HSV2) in 15% compared to 17%, 4%, and 4% in CR controls respectively. Combined, a total of 60% of PASC patients have a positive MENSA for SARS2, EBV, CMV, and/or HSV2. MENSA offers a unique antibody snapshot to reveal the underlying viral drivers in long-COVID thus demonstrating the persistence of SARS2 and reactivation of viral herpes in 60% of PASC patients. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=181 HEIGHT=200 SRC="FIGDIR/small/24310017v1_ufig1.gif" ALT="Figure 1"> View larger version (51K): org.highwire.dtl.DTLVardef@1a30be5org.highwire.dtl.DTLVardef@16203ecorg.highwire.dtl.DTLVardef@1ef9448org.highwire.dtl.DTLVardef@1f01045_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection 97%
- Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses 96%
- Antibody therapy reverses biological signatures of COVID-19 progression 96%
Similar papers in this journal
- Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms 96%
- Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity 96%
- Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19 96%
Similar papers in this journal
- Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments 95%
- Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during convalescent plasma therapy 95%
- Dose-dependent regulation of immune memory responses against HIV by saponin monophosphoryl lipid A nanoparticle adjuvant 94%
Similar papers in this journal
- Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2 96%
- Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity 95%
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.